Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELC NYSE:PACS NASDAQ:SGRY NYSE:THC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$142.53+1.6%$120.56$10.26▼$151.02$6.84B0.091.26 million shs660,710 shsPACSPACS Group$37.72+1.9%$34.51$7.50▼$43.08$5.86B-0.03910,935 shs928,591 shsSGRYSurgery Partners$13.28-1.6%$13.23$11.41▼$24.10$1.76B1.991.77 million shs1.04 million shsTHCTenet Healthcare$177.96-5.0%$195.29$146.60▼$247.21$16.14B1.31.74 million shs1.48 million shs7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+7.06%+12.75%+16.86%+31.43%+1,217.75%PACSPACS Group+0.31%-10.22%+2.60%-4.26%+250.10%SGRYSurgery Partners-1.46%-5.73%-5.73%-12.12%-41.85%THCTenet Healthcare-1.59%-4.34%-1.98%-17.60%+11.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$142.53+1.6%$120.56$10.26▼$151.02$6.84B0.091.26 million shs660,710 shsPACSPACS Group$37.72+1.9%$34.51$7.50▼$43.08$5.86B-0.03910,935 shs928,591 shsSGRYSurgery Partners$13.28-1.6%$13.23$11.41▼$24.10$1.76B1.991.77 million shs1.04 million shsTHCTenet Healthcare$177.96-5.0%$195.29$146.60▼$247.21$16.14B1.31.74 million shs1.48 million shs7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+7.06%+12.75%+16.86%+31.43%+1,217.75%PACSPACS Group+0.31%-10.22%+2.60%-4.26%+250.10%SGRYSurgery Partners-1.46%-5.73%-5.73%-12.12%-41.85%THCTenet Healthcare-1.59%-4.34%-1.98%-17.60%+11.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 2.83Moderate Buy$149.304.75% UpsidePACSPACS Group 2.71Moderate Buy$48.0027.25% UpsideSGRYSurgery Partners 2.58Moderate Buy$22.1867.03% UpsideTHCTenet Healthcare 2.86Moderate Buy$244.1637.20% UpsideCurrent Analyst Ratings BreakdownLatest SGRY, THC, CELC, and PACS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026CELCCelcuity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026PACSPACS Group Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $52.005/18/2026CELCCelcuity HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$165.00 ➝ $185.005/15/2026CELCCelcuity Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$150.00 ➝ $183.005/15/2026CELCCelcuity Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$157.005/14/2026PACSPACS Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2026PACSPACS Group OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $48.005/6/2026SGRYSurgery Partners Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.005/6/2026SGRYSurgery Partners Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/5/2026THCTenet Healthcare BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$257.00 ➝ $238.005/5/2026THCTenet Healthcare Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$245.00 ➝ $210.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$1.10 per shareN/APACSPACS Group$5.29B1.13$1.63 per share23.15$6.58 per share5.73SGRYSurgery Partners$3.31B0.52$1.68 per share7.90$23.69 per share0.56THCTenet Healthcare$21.31B0.72$26.32 per share6.76$77.93 per share2.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$177.04M-$3.90N/A3,563.25N/AN/A-244.61%-50.22%N/APACSPACS Group$191.54M$1.5623.7215.461.134.49%26.47%4.36%N/ASGRYSurgery Partners-$77.90M-$0.60N/A53.129.56-2.28%1.04%0.41%8/4/2026 (Estimated)THCTenet Healthcare$1.41B$19.239.2510.081.247.94%25.55%5.15%7/28/2026 (Estimated)Latest SGRY, THC, CELC, and PACS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CELCCelcuity-$1.07-$0.97+$0.10-$0.97$2.94 millionN/A5/11/2026Q1 2026PACSPACS Group$0.42$0.50+$0.08$0.50$1.36 billion$1.42 billion5/5/2026Q1 2026SGRYSurgery Partners-$0.15-$0.03+$0.12-$0.28$797.69 million$810.90 million4/30/2026Q1 2026THCTenet Healthcare$4.21$4.82+$0.61$8.01$5.39 billion$5.37 billion3/25/2026Q4 2025CELCCelcuity-$1.06-$0.97+$0.09-$0.97$1.28 millionN/A3/2/2026Q4 2025SGRYSurgery Partners$0.31$0.12-$0.19-$0.12$866.54 million$885.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/ASGRYSurgery PartnersN/AN/AN/AN/AN/ATHCTenet HealthcareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity6.0412.3112.31PACSPACS Group0.270.990.99SGRYSurgery Partners1.171.861.69THCTenet Healthcare1.961.361.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%PACSPACS GroupN/ASGRYSurgery PartnersN/ATHCTenet Healthcare95.44%Insider OwnershipCompanyInsider OwnershipCELCCelcuity13.33%PACSPACS Group70.10%SGRYSurgery Partners2.70%THCTenet Healthcare0.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4048.77 million42.27 millionOptionablePACSPACS Group47,455158.27 million47.32 millionOptionableSGRYSurgery Partners16,000130.79 million127.26 millionOptionableTHCTenet Healthcare99,00086.14 million85.30 millionOptionableSGRY, THC, CELC, and PACS HeadlinesRecent News About These CompaniesTenet Healthcare (THC) slides as investors weigh ongoing Leapfrog litigation headlines and post-earnings recalibration3 hours ago | quiverquant.comQInvestors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to KnowMay 21 at 10:01 AM | zacks.comHere's Why Tenet Healthcare (THC) is a Strong Momentum StockMay 20 at 10:50 AM | zacks.comGabelli Funds LLC Cuts Stock Holdings in Tenet Healthcare Corporation $THCMay 20 at 3:36 AM | marketbeat.comTenet, Leapfrog spar over legal fees in hospital ratings caseMay 19 at 5:01 PM | finance.yahoo.comIs Tenet (THC) a Buy as Wall Street Analysts Look Optimistic?May 19 at 10:30 AM | zacks.comQ2 EPS Estimate for Tenet Healthcare Decreased by AnalystMay 19 at 8:04 AM | marketbeat.comTenet system asks court to make Leapfrog pay $10.5M in legal feesMay 19 at 7:00 AM | beckershospitalreview.comBThrivent Financial for Lutherans Has $12.17 Million Position in Tenet Healthcare Corporation $THCMay 19 at 5:03 AM | marketbeat.comWall Street Analysts Think Tenet (THC) Could Surge 26.16%: Read This Before Placing a BetMay 18 at 10:56 AM | zacks.comWhat is Zacks Research's Forecast for THC Q3 Earnings?May 18 at 1:23 AM | marketbeat.comIs Tenet Healthcare (THC) Stock Undervalued Right Now?May 15, 2026 | zacks.comConifer automation helps Tenet offset Q1 headwindsMay 13, 2026 | beckershospitalreview.comBTenet Healthcare Corporation (THC) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTenet Healthcare (NYSE:THC) Rating Lowered to "Buy" at Wall Street ZenMay 11, 2026 | americanbankingnews.comTenet Healthcare (NYSE:THC) Lowered to "Buy" Rating by Wall Street ZenMay 11, 2026 | marketbeat.comPrincipal Financial Group Inc. Sells 7,237 Shares of Tenet Healthcare Corporation $THCMay 10, 2026 | marketbeat.comTenet Healthcare Corporation (NYSE:THC) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 9, 2026 | marketbeat.comWhy Tenet Healthcare (THC) is a Top Value Stock for the Long-TermMay 8, 2026 | zacks.comSwedbank AB Buys 18,750 Shares of Tenet Healthcare Corporation $THCMay 8, 2026 | marketbeat.comDanske Bank A S Reduces Stock Position in Tenet Healthcare Corporation $THCMay 7, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 20263 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026These Stocks Could Be the Biggest Winners of the 2026 MidtermsBy Chris Markoch | May 18, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026SGRY, THC, CELC, and PACS Company DescriptionsCelcuity NASDAQ:CELC$142.53 +2.19 (+1.56%) Closing price 04:00 PM EasternExtended Trading$143.83 +1.30 (+0.91%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.PACS Group NYSE:PACS$37.72 +0.72 (+1.95%) Closing price 03:59 PM EasternExtended Trading$36.66 -1.06 (-2.81%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.Surgery Partners NASDAQ:SGRY$13.28 -0.21 (-1.56%) Closing price 04:00 PM EasternExtended Trading$13.28 +0.01 (+0.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.Tenet Healthcare NYSE:THC$177.96 -9.46 (-5.05%) Closing price 03:59 PM EasternExtended Trading$177.76 -0.20 (-0.11%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; tertiary care services, such as cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; quaternary care services in heart and kidney transplants; and limb salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging, surgical robotic, and telemedicine access services. In addition, it offers a range of procedures and services, such as orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; pain management; otolaryngology; ophthalmology; and urology. It operates hospitals, ambulatory surgery centers, imaging centers, surgical hospitals, off-campus emergency departments, and micro-hospitals. Tenet Healthcare Corporation was founded in 1967 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
